From tissue to peptide.
Follow the evidence.
The Cartalax investigation opened a broader archive: parent tissue preparations, molecular identification papers, synthetic peptides and the clinical reports that belong to each.
Educational information only—not medical advice. Seek a qualified healthcare professional for any condition or health concern. Historical research and proposed tissue targets are not treatment recommendations.
CARTILAGE COMPLEX
PCC and the missing trial ↗
The 2023 Phase II statement is traceable to a review. The original trial protocol and results still need recovery.
DEFINED TRIPEPTIDECartalax / AED ↗
Composition analysis, an old-rat jaw study, cell experiments and a separate patent-reported human comparison.
The bioregulator research matrix.
These rows map research relationships, not combinations to take. Molecular identification, parent-extract trials and synthetic-peptide experiments answer different questions.
| Tissue / records | Parent preparation → peptide | Molecular link | Human research & unresolved gap |
|---|---|---|---|
| Cartilage & bonePCC ↗ · Cartalax ↗ | Cartilage polypeptide complex (PCC) Cartalax / AED | The 2020 UHPLC–MS paper reports AED in cartilage complex. The 2023 review describes PCC as a mixture spanning 75–846 Da.Source record ↗Source record ↗ | PCC: Phase II was reported in a 2023 review; underlying trial not recovered. AED: a separate 29-patient comparison appears in patent RU2299741C1.Recover the PCC trial identifier, exact formulation, protocol and results. The patent reports symptom changes without significant radiographic change; neither source establishes cartilage regeneration. |
| BrainCortexin ↗ · Pinealon ↗ · Cortagen ↗ | Cortexin / brain polypeptide preparations Pinealon / EDR; separate Cortagen research | The 2020 analytical paper detects EDR in brain complex. The broader neuropeptide literature discusses Cortexin and short peptides; molecular detection alone does not equate preparations.Source record ↗Source record ↗ | Cortexin has condition-specific clinical reports and ESCORT. Its stroke evidence needs the independent Cochrane assessment alongside positive original reports.Do not transfer Cortexin clinical results to Pinealon or Cortagen. Cortagen’s direct parent-product characterization and additional primary studies remain recovery targets. |
| Pineal glandEpithalamin ↗ · Epitalon ↗ | Epithalamin Epitalon / AEDG | The 2017 analytical study detected AEDG in pineal polypeptide complex, after its earlier design from amino-acid composition.Source record ↗Source record ↗ | The 12-year cardiovascular report, 266-person gerontology report and melatonin observations concern Epithalamin extract.Extract findings do not establish equivalent benefits for synthetic AEDG. Check cohort overlap, methods and independent replication before interpreting longevity claims. |
| ThymusThymalin ↗ · Thymogen ↗ · Vilon ↗ | Thymalin Thymogen / EW; Vilon / KE | The 2021 composition paper identifies KE and EDP in Thymalin and cites prior detection of EW. It distinguishes peptide design from subsequent molecular detection.Source record ↗Source record ↗ | The 2013 review covers Thymalin, Thymogen and Vilon, but its original trials require separate appraisal. The 266-person aging report concerns the extracts Thymalin and Epithalamin.Avoid assigning extract outcomes to individual peptides. Vilon cell-culture findings are mechanistic, not evidence of human rejuvenation. |
| Blood vesselsVasolin / Slavinorm ↗ · Vesugen ↗ · KED ↗ | Vasolin / Slavinorm Vesugen / KED | KED was detected in vessel complex in the 2020 composition paper. Vesugen is the KED short-peptide entry; the separate KED route preserves sequence-based research navigation.Source record ↗Source record ↗ | The vessel-complex review describes animal models. The existing occupational combination report does not isolate Vesugen.Same sequence does not establish equivalence of commercial formulations. KED cell and mouse findings cannot inherit the extract’s proposed clinical effects. |
| LiverVentvil ↗ · Livagen ↗ | Ventvil Livagen / KEDA | The 2020 Russian review discusses the liver complex and defined tetrapeptide together as separate experimental interventions.Source record ↗ | The recovered review describes animal and cell models of fibrosis/hepatitis, not a human treatment trial.Original model-specific papers and molecular characterization remain necessary. A shared research program is not proof of identical composition or effects. |
| HeartCardiogen ↗ | Heart polypeptide complex (review-described) Cardiogen / AEDR | The cardiovascular review reports detection of AEDR in heart complex. Its original analytical source has not been independently recovered here.Source record ↗Source record ↗ | The highlighted myocardial-infarction result is preclinical and traces to US7662789B2, cited by the review.Preserve the patent provenance. No human Cardiogen cardiovascular benefit is established by these records. |
| ProstateProstatilen ↗ · Prostamax ↗ | Prostatilen Prostamax (adjacent short-peptide program) | Tissue-level research association only in this collection; direct molecular derivation of Prostamax from the clinical Prostatilen formulation has not been established.Source record ↗Source record ↗ | The 307-patient and 52-patient reports concern Prostatilen extract, with control and methods limitations.Do not assign the Prostatilen cohorts to Prostamax or treat uncontrolled improvement as proof of efficacy. |
| RetinaRetinalamin ↗ · Normophthal ↗ | Retinalamin Normophthal (adjacent short-peptide program) | Shared tissue theme, not a verified product-to-sequence derivation in this collection.Source record ↗Source record ↗ | The glaucoma report compares active Retinalamin administration routes; its abstract uses the unit “498 patients (eyes)”.An active-route comparison cannot establish benefit versus no treatment. Retinalamin findings cannot be transferred to Normophthal. |
| Bronchial mucosaChonluten ↗ · Bronchogen ↗ | Bronchial-mucosa polypeptide complex Chonluten / EDG; Bronchogen / AEDL | The 2020 UHPLC–MS report identifies EDG and AEDL in bronchial-mucosa complex.Source record ↗Source record ↗ | Molecular identification is not a clinical trial. No newly appraised human report is added for either peptide in this update.Recover sequence-specific original experiments and clinical protocols; do not infer respiratory treatment or hazardous-exposure protection. |
| PancreasPancragen ↗ | Pancreatic polypeptide complex Pancragen / KEDW | The 2020 composition paper reports KEDW in pancreatic complex.Source record ↗Source record ↗ | Clinical claims in the analytical paper’s introduction remain cited leads; they are not a new clinical experiment in that paper.Retrieve the original patient reports, comparators and preparation details before interpreting metabolic outcomes. |
| Testicular research targetTestagen ↗ | Parent preparation not established here Testagen | The 2013 short-peptide catalogue is the traceable source retained for this entry.Source record ↗ | No additional compound-specific primary clinical report was recovered in the Cartalax update.The research target is not a demonstrated treatment indication. Original identity, composition and clinical sources remain explicit gaps. |
Three distinctions that change the reading.
Detected is different from designed.
The 2017 pineal and 2020 multi-organ papers provide analytical evidence for particular sequences. Other relationships remain review-reported or tissue-level associations.
A patent is its own source type.
The AED patent describes a small human comparison. The Cardiogen infarction claim traces to another patent. Both remain visible with their provenance and limitations.
Reviews do not multiply trials.
Later reviews often cite the same early studies. Cortexin’s independent Cochrane assessment appears alongside its original clinical reports; neither review citations nor follow-up papers are independent replications.
Russian historical review ↗ · Multi-organ composition paper / PDF ↗ · Independent stroke evidence assessment ↗
What remains open.
The PCC trial registration and outcomes, original molecular characterization behind some parent–peptide claims, and compound-specific clinical reports for catalogue-only entries remain explicit recovery targets. This collection does not claim an exhaustive bibliography or a completed systematic review.
Explore bibliography & PDFs ↗